360
Participants
Start Date
November 30, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
R21
A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein
RH5.1
A soluble protein vaccine against the RH5 antigen
R78C
A soluble RIPR EGF-CyRPA fusion protein vaccine
Matrix-M™
A saponin-based vaccine adjuvant
Rabivax-S
Rabivax-S is an inactivated, freeze-dried, single-dose vaccine. The vaccine contains purified, inactivated rabies antigen produced using Vero ATCC CCL 81 cells as the cell substrate, Pitman Moore (PM3218) as the virus strain, and sucrose, glycine and HSA (Human Serum Albumin) as excipients
Menveo
Menveo is a tetravalent meningitis vaccine that consists of one vial of MenA powder and one vial of Men CWY solution.
Avaxim 80
Avaxim 80 is an inactivated, adsorbed hepatitis A vaccine. Each immunising dose contains 80 antigen units of inactivated hepatitis A virus (GBM strain).
Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro
Institut de Recherche en Sciences de la Sante, Burkina Faso
OTHER_GOV
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
University of Oxford
OTHER